Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-02-15
2011-02-15
Epps-Smith, Janet L (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024300, C536S024310, C536S024500
Reexamination Certificate
active
07888324
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
REFERENCES:
patent: 5220006 (1993-06-01), Ross et al.
patent: 5434058 (1995-07-01), Davidson et al.
patent: 5618674 (1997-04-01), Sanchez-Pescador et al.
patent: 5656612 (1997-08-01), Monia
patent: 5712257 (1998-01-01), Carter
patent: 5786206 (1998-07-01), Smith et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5945290 (1999-08-01), Cowsert
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6033910 (2000-03-01), Monia et al.
patent: 6096516 (2000-08-01), Kwak et al.
patent: 6156315 (2000-12-01), Goldberg et al.
patent: 6172216 (2001-01-01), Bennett et al.
patent: 6184212 (2001-02-01), Miraglia et al.
patent: 6512161 (2003-01-01), Rouy et al.
patent: 6534277 (2003-03-01), Hancock et al.
patent: 6949367 (2005-09-01), Dempcy et al.
patent: 2003/0087853 (2003-05-01), Crooke et al.
patent: 2003/0215943 (2003-11-01), Crooke et al.
patent: 2004/0214325 (2004-10-01), Crooke et al.
patent: 2004/0241651 (2004-12-01), Olek et al.
patent: 2005/0009088 (2005-01-01), Crooke et al.
patent: 2005/0287558 (2005-12-01), Crooke et al.
patent: 2006/0009410 (2006-01-01), Crooke et al.
patent: 2006/0035858 (2006-02-01), Geary et al.
patent: 0332435 (1989-09-01), None
patent: 0530794 (1993-03-01), None
patent: 0 911 344 (1999-04-01), None
patent: WO 97/35538 (1997-10-01), None
patent: WO 98/20166 (1998-05-01), None
patent: WO 98/32846 (1998-07-01), None
patent: WO 98/36641 (1998-08-01), None
patent: WO 99/18237 (1999-04-01), None
patent: WO 99/18986 (1999-04-01), None
patent: WO 99/35241 (1999-07-01), None
patent: WO0000504 (2000-01-01), None
patent: WO 00/56916 (2000-09-01), None
patent: WO 00/56920 (2000-09-01), None
patent: WO 01/12789 (2001-02-01), None
patent: WO 01/30354 (2001-03-01), None
patent: WO 01/30395 (2001-05-01), None
patent: WO 01/52902 (2001-07-01), None
patent: WO 01/77384 (2001-10-01), None
patent: WO 02/26768 (2002-04-01), None
patent: WO 03/011887 (2003-02-01), None
patent: WO 03/074723 (2003-09-01), None
patent: WO 03/097662 (2003-11-01), None
patent: WO 2004/044181 (2004-05-01), None
patent: WO 2005/049621 (2005-06-01), None
Tang et al. The inhibitory effect of antisnse oligonucleotides on apoplipoprotein B expression in liver cells of rat. Zhongguo Dongmai Yinghua ZaZhi Bianjibu (Chinese Journal), (1999), vol. 7, No. 4, pp. 315-318.
Branch, TIBS, vol. 23, 1998, pp. 45-50.
Agrawal et al. Antisense therapeutics: is it as simple as complementary base recognition? Molecular Medicine Today, Feb. 2000, vol. 6, pp. 72-81.
John Rossi, Introductory Remarks on the General Application of Antisense RNAs and RIbozymes. Methods: A Companion to Methods in Enzymology. vol. 5, pp. 1-5, 1993.
Tang et al. The Inhibition of Antisense Oligodeoxynucleotides on the Expression of Apolipoprotein B in Rat Liver Cells. Chinese Journa of Arteriosclerosis. vol. 7, No. 4, 1997. Translation.
Tang et al. see IDS of Oct. 27, 2003.
GenBank Accession No. NM—000384 , Oct. 31, 2000, (Huang et al.).
Borén et al., “A Simple and Efficient Method for Making Site-directed Mutants, Deletions, and Fusions of Large DNA Such as P1 and BAC Clones”,Genome Research1996 1123-1130.
Davidson et al., “Apolipoprotein B:mRNA Editing, Lipoprotein Assembly, and Presecretory Degradation”,Annu. Rev. Nutr. 2000 20:169-193.
Farese et al., “Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes”,Proc. Natl. Acad. Sci. USA1995 92:1774-1778.
Deeb et al., “Chromosomal localization of the human apolipoprotein B gene and detection of homologous RNA in monkey intestine”,Proc. Natl. Acad. Sci. USA1986 83:419-422.
Hajjar et al., “The Role of Lipoprotein(a) In Atherogenesis and Thrombosis”,Annu. Rev. Med. 1996 47:423-442.
Innerarity et al., “Familial defective apolipoprotein B-00:Low density lipoproteins with abnormal receptor binding”,Proc. Natl. Acad. Sci. USA1987 84:6919-6923.
Katan et al., “Characteristics of Human Hypo- and Hyperresponders to Dietary Cholesterol”,American Journal of Epidemiology1987 125 (3):387-399.
Kim et al., “Genetically modified mice for the study of apolipoprotein B”,Journal of Lipid Research1998 39:703-723.
Law et al., “Human apolipoprotein B-100:Cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2”,Proc. Natl. Acad. Sci. USA1985 82:8340-8344.
McCormick et al., “Transgenic Mice Expressing Human ApoB95 and ApoB97”,The Journal of Biological Chemistry1997 272(38) :23616-23622.
Nishina et al., “Synthetic low and high fat diets for the study of atherosclerosis in the mouse”,Journal of Lipid Research1990 31:859-869.
Nowak-Göttl et al., “Lipoprotein (a):Its Role in Childhood Thromboembolism”,Pediatrics1997 99(6):1-3.
Sandkamp et al., “Lipoprotein(a) Is an Independent Risk Factor for Myocardial Infarction at a Young Age”,Clin. Chem. 1990 36/1:20-23.
Seed et al., “Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia”,The New England Journal of Medicine1990 1494-1498.
Véniant et al., “Susceptibility to Atherosclerosis in Mice Expressing Exclusively Apolipoprotein B48 or Apolipoprotein B100”,J. Clin. Invest. 1997 100(1):180-188.
Vessby et al., “Diverging Effects of Cholestyramine on Apolipoprotein B and Lipoprotein Lp(a)”,Atherosclerosis1982 44:61-71.
Branch, A.D., “A good antisense molecule is hard to find,”TiBS23: 45-50 (1998).
Tang et al., “The Inhibition of Antisense Oligodeoxynucleotides on the Expression of Apolipoprotein B in Rat Liver Cells,”Chinese Journal of Arteriosclerosis7(4) (1999) (English translation).
Tanaka et al., “Regulation of Apolipoprotein B Production and Secretion in response to the Change of Intracellular Cholesteryl Ester Contents in Rabbit Hepatocytes,”The Journal of Biological Chemistry268(17): 12713-12718 (1993).
U.S. Appl. No. 60/159,462, Eggerman et al.
Parrish et al., Molecular Cell 2000, vol. 6, pp. 1077-1087 (2000).
Hammond et al., Post-transcriptional gene silencing by double-stranded RNA, Nature Genetics 2001, vol. 2: 110-119 (Feb. 2001).
Patil et al., DNA-based therapeutics and DNA delivery systems: A comprehensive review, 2005. The AAPS Journal, vol. 7, pp. E61-E77.
De Mesmaeker, et al. 1995.Backbone Modifications in Oligonucleotides and Peptide Nucleic Acid Systems. Current Opinion in Structural Chemistry, 5: 343-355.
Supplementary Partial European Search Report from PCT/US0224247 dated Jul. 27, 2006.
EMBL Accession No. A23827, Apr. 2, 1995.
EMBL Accession No. A13429, Oct. 5, 1994.
EMBL Accession No. A97152, Jan. 26, 2000.
GENESEQ Accession No. AAA07969, Jan. 29, 2001.
EMBL Accession No. AR 152836, Aug. 9, 2001.
EMBL Accession No. 113154, Aug. 2, 1995.
GENESEQ Accession No. AAA28208, Jan. 29, 2001.
GENESEQ Accession No. AAV39607, Sep. 28, 1998.
Crooke, S. T., “Basic Principles of Antisense Therapeutics,”Antisense Research and Application(1998) Springer-Verlag Press, Berlin, pp. 1-50.
EMBL Accession No. L27195, Jan. 6, 1994.
Graham, M. J. et al., “Inhibition of ApoB-100 as a Therapeutic Strategy for the Treatment of Hyperlipidermias,”AHA Abstract(2002) ID: 548.
Huang, L.-S. et al., “Hypobetalipoproteinemia due to an apolipoprotein B gene exon 21 deletion derived by Alu-Alu recombination,”J. Biol. Chem. (1989) 264(19):11394-11400.
Jen, K.-Y. et al., “Suppression of Gene Expression by Targeted Disruption of
Crooke Rosanne M.
Graham Mark J.
Epps-Smith Janet L
Genzyme Corporation
Jones Day
LandOfFree
Antisense modulation of apolipoprotein B expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of apolipoprotein B expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of apolipoprotein B expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619659